Stella Pharma Corporation (TYO:4888)

Market Cap	13.51B
Revenue (ttm)	323.00M
Net Income (ttm)	-667.00M
Shares Out	34.03M
EPS (ttm)	-20.41
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	233,700
Average Volume	251,535
Open	393.00
Previous Close	401.00
Day's Range	386.00 - 409.00
52-Week Range	260.00 - 602.00
Beta	0.98
RSI	39.19
Earnings Date	May 9, 2025

About Stella Pharma

Stella Pharma Corporation engages in the research, development, manufacturing, and distribution of pharmaceuticals. The company develops drugs for boron neutron capture therapy (BNCT). Its product includes SPM-011, a boron-containing drug for BNCT used for treating head and neck cancer, recurrent malignant glioma and meningioma, and malignant melanoma and angiosarcoma. The company was incorporated in 2007 and is headquartered in Osaka, Japan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 44
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4888

Financial Performance

In 2023, Stella Pharma's revenue was 269.00 million, an increase of 17.47% compared to the previous year's 229.00 million. Losses were -763.00 million, -1.93% less than in 2022.